Financial PositionThe strategic financing agreement results in approximately $23 million of working capital to fund operations and advance the development of Halneuron.
Regulatory ApprovalThe company has received FDA special protocol assessment approval to conduct a Phase 3 registration-directed study of Halneuron in the U.S., Canada, and E.U.
Strategic PartnershipsThe business combination with Wex Pharmaceuticals expands the pipeline in the fatigue and pain space, enhancing Dogwood Therapeutics' position in the market.